

Elisabetta Bugianesi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2635016/elisabetta-bugianesi-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

134
papers

12,986
citations

50
h-index

113
g-index

152
ext. papers

18,465
ext. citations

8.1
avg, IF

6.59
L-index

#	Paper	IF	Citations
134	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 11-20	24.2	1902
133	Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. <i>Gastroenterology</i> , 2002 , 123, 134-40	13.3	1170
132	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020 , 73, 202-209	13.4	764
131	Insulin resistance: a metabolic pathway to chronic liver disease. <i>Hepatology</i> , 2005 , 42, 987-1000	11.2	601
130	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019 , 69, 2672-2682	11.2	557
129	A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1082-90	0.7	516
128	Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. <i>Nutrients</i> , 2013 , 5, 1544-60	6.7	474
127	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	4.0	425
126	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15080	51.1	366
125	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. <i>Hepatology</i> , 2004 , 39, 179-87	11.2	342
124	Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3498-504	5.6	322
123	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 748-755.e3	6.9	311
122	Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. <i>Annual Review of Medicine</i> , 2016 , 67, 103-17	17.4	293
121	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
120	Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Journal of Hepatology</i> , 2011 , 54, 64-71	13.4	192
119	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021 , 592, 450-456	50.4	164
118	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. <i>Hepatology</i> , 2018 , 67, 145-158	11.2	162

117	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
116	Interferon- γ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015 , 6, 6422	17.4	127
115	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. <i>Hepatology</i> , 2006 , 44, 1648-55	11.2	126
114	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. <i>Hepatology</i> , 2009 , 50, 697-706	11.2	117
113	Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 1536-43	4	115
112	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
111	Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	111
110	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020 , 71, 1213-1227	12.7	104
109	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. <i>Liver International</i> , 2016 , 36, 1563-1579	7.9	96
108	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015 , 35, 1566-73	7.9	94
107	Should we undertake surveillance for HCC in patients with NAFLD?. <i>Journal of Hepatology</i> , 2018 , 68, 326-334	13.4	93
106	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	88
105	Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. <i>Clinics in Liver Disease</i> , 2016 , 20, 313-24	4.6	83
104	Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e87523	3.7	83
103	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 682-90	13.4	79
102	NASH in Lean Individuals. <i>Seminars in Liver Disease</i> , 2019 , 39, 86-95	7.3	77
101	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018 , 69, 878-885	13.4	75
100	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016 , 7, 12757	17.4	73

99	IFN- β , not IFN- α , likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017 , 49, 795-800	36.3	72
98	Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. <i>Hepatobiliary Surgery and Nutrition</i> , 2015 , 4, 109-16	2.1	68
97	The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2016 , 36, 1549-57	7.9	67
96	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019 , 71, 1012-1021	13.4	66
95	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016 , 64, 34-46	11.2	65
94	379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2014 , 146, S-909	13.3	64
93	Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. <i>Journal of Medical Virology</i> , 2018 , 90, 320-327	19.7	57
92	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1625-1633.e1	6.9	56
91	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016 , 64, 390-398	13.4	55
90	Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. <i>Seminars in Liver Disease</i> , 2015 , 35, 236-49	7.3	54
89	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. <i>Diabetologia</i> , 2017 , 60, 1873-1882	10.3	51
88	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
87	Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 479	6.3	51
86	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021 , 74, 775-782	13.4	50
85	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. <i>Current Diabetes Reports</i> , 2007 , 7, 175-80	5.6	46
84	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019 , 70, 494-500	13.4	46
83	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016 , 11, e0163069	3.7	45
82	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019 , 9, 3682	4.9	42

81	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2310-2319.e6	6.9	42
80	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , 2015 , 8, 1037-46	4.1	42
79	Hypoxia-inducible factor 2 α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein. <i>Hepatology</i> , 2018 , 67, 2196-2214	11.2	42
78	Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?. <i>Digestive and Liver Disease</i> , 2016 , 48, 105-11	3.3	42
77	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 333-42	3.3	42
76	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016 , 63, 107-16	11.2	42
75	Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017 , 12, e0172575	3.7	38
74	Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	32
73	Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. <i>BMC Gastroenterology</i> , 2019 , 19, 56	3	31
72	Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1163-1169.e1	6.9	31
71	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	31
70	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2021 , 372, m4747	5.9	31
69	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29
68	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
67	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020 , 71, 1953-1966	11.2	27
66	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019 , 114, 916-928	0.7	27
65	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2021 ,	19.2	27
64	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017 , 37, 1389-1396	7.9	26

63	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2004 , 18, 1105-16	2.5	26
62	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018 , 69, 1155-1163	13.4	25
61	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1277-1286	0.7	22
60	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016 , 6, 31421	4.9	22
59	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 806-815.e5	6.9	21
58	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 786-794	13.4	21
57	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , 2011 , 48, 337-343	3.9	20
56	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
55	A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 80-82	24.2	19
54	Global multi-stakeholder endorsement of the MAFLD definition.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	18
53	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021 , 161, 1657-1669	13.3	17
52	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	16
51	Reply:. <i>Hepatology</i> , 2006 , 43, 1168-1169	11.2	16
50	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2016 , 48, 55-61	3.3	16
49	Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018 , 38, 715-723	7.9	15
48	Hepatic and cardiac steatosis: are they coupled?. <i>Heart Failure Clinics</i> , 2012 , 8, 663-70	3.3	14
47	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2021 ,	4.0	12
46	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. <i>Metabolites</i> , 2021 , 11,	5.6	12

45	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
44	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?. <i>Diabetologia</i> , 2016 , 59, 1145-7	10.3	11
43	The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
42	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , 2019 , 110, 401-409	2.2	9
41	Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. <i>Cells</i> , 2019 , 9,	7.9	9
40	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021 , 13,	6.6	9
39	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	9
38	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020 , 12,	6.6	7
37	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
36	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020 , 96, 114985	2.9	7
35	Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	7
34	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β dependent mechanisms. <i>Scientific Reports</i> , 2019 , 9, 1439	4.9	6
33	Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. <i>Digestive and Liver Disease</i> , 2015 , 47, 405-10	3.3	6
32	Fatty liver disease: putting the spotlight on a silent menace for young adults. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 236-238	18.8	6
31	The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. <i>Frontiers in Endocrinology</i> , 2021 , 12, 716533	5.7	6
30	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	6
29	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with ES1 for 8 or 12 Weeks: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
28	Mechanisms for increased risk of diabetes in chronic liver diseases. <i>Liver International</i> , 2020 , 40, 2489-2499	4.9	5

27	Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2004 , 39, 1749-1749	11.2	5
26	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1289-1292	0.7	5
25	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021 , 70, 103521	8.8	5
24	NAFLD and Hepatocellular Carcinoma: How Big a Problem is This Really?. <i>Current Hepatology Reports</i> , 2014 , 13, 113-118	1	4
23	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
22	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	4
21	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
20	Natural history of NASH. <i>Liver International</i> , 2021 , 41 Suppl 1, 78-82	7.9	4
19	The next decade of metabolism. <i>Nature Metabolism</i> , 2019 , 1, 2-4	14.6	3
18	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn'S Disease: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
17	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1253-1266	4.2	3
16	Obesity: Childhood obesity: time bomb for future burden of chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 506-7	24.2	2
15	Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.. <i>Journal of Pathology</i> , 2022 ,	9.4	2
14	Hepatocyte-Specific Deletion of HIF2 β Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 ,	7.9	2
13	Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. <i>Liver International</i> , 2021 , 41, 1999-2008	7.9	2
12	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021 , 10,	4.9	2
11	Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles.. <i>Hepatology</i> , 2022 ,	11.2	2
10	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. <i>JHEP Reports</i> , 2022 , 4, 100477	10.3	2

9	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020 , 7, 616212	4.9	1
8	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020 , 15, e0243590	3.7	0
7	Inflammatory Bowel Disease Nurse-Practical Messages.. <i>Nursing Reports</i> , 2021 , 11, 229-241	0.8	0
6	The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality. <i>Current Hepatology Reports</i> , 2018 , 17, 336-344	1	0
5	Reply to "Definition of Small for Gestational Age and Low Birthweight". <i>American Journal of Gastroenterology</i> , 2018 , 113, 442	0.7	
4	Diabetes and NAFLD: Why is the Connection Important?62-70		
3	Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 1016-111	2.4	
2	Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?". <i>Digestive and Liver Disease</i> , 2016 , 48, 1101-2	3.3	
1	Reply. <i>Hepatology</i> , 2018 , 67, 1178-1180	11.2	